文献速递淋巴瘤

MYD88和/或CD79B突变对弥漫大B细胞淋巴瘤患者中枢神经系统复发的影响

Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2025-04-22

本研究纳入270例新诊断弥漫大B细胞淋巴瘤(DLBCL)患者,中位随访6.65年,20例发生中枢神经系统(CNS)复发。55例(20%)携带MYD88/CD79B突变,单因素分析显示该突变与CNS复发风险升高显著相关。在CNS-IPI低或中危患者中,突变者CNS复发率高于无突变者(18.8% vs. 1.2%)。

要点

  • MYD88/CD79B突变在初诊DLBCL中占20%,单因素分析显示与CNS复发风险升高显著相关。
  • 突变患者2年和6年累积CNS复发率分别为10.9%和18.1%,中位至CNS复发时间11.5个月。
  • CNS-IPI低/中危患者中突变者CNS复发率18.8% vs. 无突变者1.2%;高危患者无论突变状态CNS复发均高。

核心结论

  • 本研究结果提示MYD88/CD79B突变可能作为DLBCL中枢神经系统复发的预测标志物,但需在更多队列中进一步验证。

研究设计与样本

  • 研究纳入270例新诊断弥漫大B细胞淋巴瘤患者,检测MYD88L265P和/或CD79BY196突变,中位随访6.65年。

主要发现

  • 中位随访6.65年期间,20例患者发生中枢神经系统复发。
  • 55例(20%)患者携带MYD88/CD79B突变,单因素分析显示该突变与CNS复发风险升高显著相关。
  • 总体中位至CNS复发时间为11.5个月,携带MYD88/CD79B突变的患者CNS复发在2年后仍持续发生。
  • 携带MYD88/CD79B突变患者的2年和6年累积CNS复发率分别为10.9%和18.1%。
  • CNS-IPI低或中危患者中,携带MYD88/CD79B突变者CNS复发率高于无突变者(18.8% vs. 1.2%)。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文指出需在更多队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study examined the effect of myeloid differentiation primary response gene 88 mutation L265P (MYD88L265P) and/or cluster of differentiation 79B gene mutation Y196 (CD79BY196) (MYD88/CD79B) on central nervous system (CNS) relapse in 270 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Over a median follow-up of 6.65 years, 20 patients experienced CNS relapse. Fifty-five (20%) patients had MYD88/CD79B mutations, and these mutations were significantly associated with an increased risk of CNS relapse in univariable analysis. The overall median time to CNS relapse was 11.5 months, with relapses continuing beyond 2 years in patients harbouring MYD88/CD79B mutations. These patients had 2- and 6-year cumulative CNS relapse rates of 10.9% and 18.1% respectively. Among patients classified as having low or intermediate risk according to the CNS-International Prognostic Index (CNS-IPI), those with MYD88/CD79B mutations exhibited higher CNS relapse rates than those without these mutations (18.8% vs. 1.2%). In contrast, patients with high risk showed high CNS relapse, regardless of the mutation status, suggesting heterogeneous mechanisms underlying CNS relapse. In conclusion, the results of this study suggest that MYD88/CD79B mutations may serve as a predictive marker for CNS relapse in DLBCL, although further validation in additional cohorts is warranted.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Suzuki T, Fujii K, Matsunaga N, et al. Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma. Br J Haematol. 2025. PMID: 40263702. doi:10.1111/bjh.20099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。